GLP-1 Weight Loss: Medicines, Results and Getting Started
This is the hub page for GLP-1 weight loss on GLPKit. It brings together the medicines used for weight management, what the large trials found on average, how results build over time, and where to go next for the details on each drug, each timeline and each common problem. It is education only, not a promise of any individual result.
The medicines behind GLP-1 weight loss
Two brands are approved specifically for chronic weight management. Wegovy contains semaglutide and is approved for adults with obesity, or overweight with a weight related condition, and for adolescents aged 12 and older. Zepbound contains tirzepatide and is approved for adults in the same weight categories, and also for moderate to severe obstructive sleep apnea in adults with obesity. Their sister brands, Ozempic and Mounjaro, contain the same ingredients but are approved for type 2 diabetes, which is why their weight effects are discussed so often even though weight management is not their labeled use.
All four are once weekly injections with slow dose increases. Wegovy builds through 0.25, 0.5, 1 and 1.7 mg steps to a maintenance dose of 2.4 mg weekly, or 1.7 mg if 2.4 mg is not tolerated. Zepbound starts at 2.5 mg, rises by 2.5 mg steps, and its maintenance doses are 5, 10 or 15 mg weekly. The brand pages on this site go deeper: Wegovy weight loss, how much weight you can lose on Zepbound, semaglutide weight loss and tirzepatide weight loss, plus Ozempic weight loss and Mounjaro weight loss for the diabetes brands.
What the trials found, on average
The two anchor results are worth stating exactly. In STEP 1, people taking semaglutide 2.4 mg lost an average of 14.9 percent of body weight at 68 weeks. In SURMOUNT-1, people taking tirzepatide lost an average of 20.9 percent at the 15 mg dose at 72 weeks. Those trials were run separately, in different populations and programs, so the figures are not a head to head comparison and do not prove one medicine beats the other for any individual. They are averages, which means many people lost less and some lost considerably more.
Averages also hide the shape of the journey. Weight tends to fall slowly in the first weeks on the starting doses, faster once maintenance doses are reached, and then to level off. The GLP-1 weight loss per week page translates the trial averages into a weekly pace, and the before and after pages for Ozempic, Mounjaro and tirzepatide describe what averages mean month by month without inventing personal stories. The GLP-1 weight loss calculator applies the published averages to your own starting weight as an estimate, clearly labeled as such.
How the weight loss happens
The medicines do not burn fat directly. They reduce appetite and food driven thinking, slow stomach emptying so meals satisfy sooner and for longer, and improve blood sugar handling. Eating less, consistently, over many months is what produces the loss, which is why the same habits that support any weight loss still matter. It also explains the two most common frustrations. Loss is gradual rather than instant, because dose increases are deliberately slow, and loss eventually slows as the body reaches a new balance, which the GLP-1 weight loss plateau page explains in detail.
Because intake falls, what you do eat carries more weight than it used to. Protein protects muscle while fat is lost, and the GLP-1 muscle loss page covers how much of the loss can be muscle and how people protect it. The eating pattern itself is set out in what to eat on GLP-1 and the GLP-1 diet pillar, and timing questions are answered in how long Ozempic takes to work and how long Wegovy takes to work.
Getting started, in general terms
Starting is always through a prescriber. These are prescription medicines, so the route is an assessment of your weight history, conditions and other medicines, a prescription if the prescriber judges it appropriate, and a plan for follow up. The how to get Ozempic page walks through prescription routes step by step, and the online GLP-1 providers page explains how to judge telehealth services by licensed clinicians, real prescriptions, pharmacy transparency and follow up care, rather than by marketing claims.
Cost shapes almost every start, because list prices are high and coverage is inconsistent. Wegovy lists at about $1,350 a month and Zepbound at about $1,060 a month, before any insurance or program. The GLP-1 cost pillar and the GLP-1 cost calculator help you model what a year of treatment could look like, and the GLP-1 insurance coverage page explains how approval usually works. Planning the money side before the first dose prevents the common problem of starting a medicine you cannot sustain.
Staying on, plateaus and stopping
These medicines are labeled for chronic use, and the evidence on stopping is sobering. In the STEP 1 extension, people regained about two thirds of the lost weight within a year of stopping semaglutide. In SURMOUNT-4, the group switched to placebo regained about half of the lost weight after stopping tirzepatide. That does not mean nobody can stop, but it does mean stopping should be a planned decision with your prescriber, with habits and monitoring in place, rather than a response to a good weigh in. The GLP-1 weight regain after stopping page covers what the trials show.
Plateaus are a normal phase, not a failure. Appetite effects settle, the body defends a lower weight less aggressively over time, and small habits drift. Before concluding a medicine has stopped working, it is worth checking dose stage, protein intake, sleep, alcohol and the slow creep of portions, all of which the plateau page works through. If side effects are the limiting factor instead, the side effect guides, starting with GLP-1 nausea remedies, cover the eating and habit changes that commonly help, and anything severe or persistent belongs with your care team promptly.
What realistic expectations look like
Realistic expectations protect people from the two common mistakes: quitting at week six because the scale has barely moved, and expecting the average to arrive on a personal schedule. The starting doses exist to let the body adapt, not to produce the headline results, and most of the trial loss accumulated over many months at maintenance doses. Weighing weekly rather than daily, tracking waist and clothing fit alongside the scale, and reviewing progress at dose milestones rather than calendar weeks all give a fairer picture of what the medicine is doing.
It is also realistic to plan for the unglamorous middle. Appetite suppression can make social meals awkward, side effects tend to flare after each increase and then settle, and there will be weeks where nothing changes despite doing everything right. None of that signals failure. What it signals is a long program behaving as long programs do. People who treat the medicine as one part of a system, with protein, sleep, movement and follow up in place, are the ones whose experience most resembles the trial averages quoted above.
Support systems that quietly decide outcomes
Two support systems decide more outcomes than any headline. The first is follow up: regular contact with the prescriber to manage dose increases, side effects and the comorbidities that travel with weight, rather than a single prescription left to run. The second is measurement that goes beyond the scale, including blood pressure, blood sugar where relevant, waist size, strength and how daily life feels. Weight is the reason most people start, but it is rarely the only number that improves, and noticing the wider changes is part of what sustains a long program through its slow middle months.
Frequently asked questions
How much weight do people lose on GLP-1 medicines on average?
In the large trials, semaglutide 2.4 mg produced an average loss of 14.9 percent of body weight at 68 weeks in STEP 1, and tirzepatide produced an average loss of 20.9 percent at the 15 mg dose at 72 weeks in SURMOUNT-1. The trials were separate and are not a head to head comparison. Individual results vary widely around any average.
How long does GLP-1 weight loss take to start?
Appetite usually changes within the first weeks, but the starting doses are low by design and are raised slowly over months. Most visible loss builds once higher doses are reached. The trial timelines ran well over a year, so this is a long program rather than a quick fix.
Which GLP-1 medicines are approved for weight loss?
Wegovy, which contains semaglutide, and Zepbound, which contains tirzepatide, are the brands approved for chronic weight management. Ozempic and Mounjaro contain the same ingredients but are approved for type 2 diabetes. Which one, if any, fits a person is a prescriber decision.
What happens to the weight if I stop?
Trial evidence shows substantial regain is common. In the STEP 1 extension, people regained about two thirds of the lost weight within a year of stopping semaglutide, and in SURMOUNT-4 the group switched to placebo regained about half after stopping tirzepatide. Stopping is best planned with your prescriber.
Do I still need to think about food and activity on these medicines?
Yes. The medicines work by reducing appetite, so eating less does the work. Protein intake, fiber, fluids and regular movement protect muscle and help results last. The eating guides on this site set out the pattern most people follow.